. (1998). Toxicol. Sci. 44,[87][88][89][90][91][92][93][94][95][96] The purpose of this study was to relate dose-dependent hepatotoxicity stemming from prolonged exposure to sublethal concentrations of the cyclic heptapeptide microcystin-LR (Mcyst) to hepatic Mcyst concentrations and protein phosphatase activity. Mcyst is a potent inhibitor of protein phosphatase types 1 and 2A (PP1 and PP2A). Twenty male Sprague-Dawley rats were infused continuously with 0, 3, 6, or 9 fig Mcyst/day for 28 days using intraperitoneal mini-osmotic pumps containing highly purified toxin or saline. At the end of 28 days, dose-dependent increases in several serum biochemical tests including sorbitol dehydrogenase, aspartate aminotransferase, y-glutamyl transferase, alkaline phosphatase, and bile acids had occurred. Serum albumin decreased in a dose-dependent fashion. Liver activity of both PP1 and PP2A decreased in a dose-dependent manner, but with a relatively greater effect on PP2A than PP1. Liver cytosol Mcyst concentrations, measured by direct competitive ELISA, also increased in a dose-dependent manner, although at a higher rate than would be predicted from the incremental increase in dose given. This disproportional increase is suggestive of the bioaccumulation of Mcyst with increasing dose. Histopathological abnormalities included hepatocellular apoptosis and cytosolic vacuolation of principally zone 3 hepatocytes. Immunohistochemical stains revealed Mcyst predominantly within pericanalicular regions of zone 3 hepatocytes. It was concluded that prolonged exposure to sublethal concentrations of Mcyst results in multiple dose-dependent hepatotoxic effects that correspond to decreased hepatic serine/threonine protein phosphatase activity and increasing cytosolic Mcyst concentrations. The disproportional increase of hepatic Mcyst concentrations observed may suggest the bioaccumulation of toxin and an increasing relative risk of hepatotOXicity With increasing dose.
The purpose of this study was to relate dose-dependent hepatotoxicity stemming from prolonged exposure to sublethal concentrations of the cyclic heptapeptide microcystin-LR (Mcyst) to hepatic Mcyst concentrations and protein phosphatase activity. Mcyst is a potent inhibitor of protein phosphatase types 1 and 2A (PP1 and PP2A). Twenty male Sprague-Dawley rats were infused continuously with 0, 3, 6, or 9 fig Mcyst/day for 28 days using intraperitoneal mini-osmotic pumps containing highly purified toxin or saline. At the end of 28 days, dose-dependent increases in several serum biochemical tests including sorbitol dehydrogenase, aspartate aminotransferase, y-glutamyl transferase, alkaline phosphatase, and bile acids had occurred. Serum albumin decreased in a dose-dependent fashion. Liver activity of both PP1 and PP2A decreased in a dose-dependent manner, but with a relatively greater effect on PP2A than PP1. Liver cytosol Mcyst concentrations, measured by direct competitive ELISA, also increased in a dose-dependent manner, although at a higher rate than would be predicted from the incremental increase in dose given. This disproportional increase is suggestive of the bioaccumulation of Mcyst with increasing dose. Histopathological abnormalities included hepatocellular apoptosis and cytosolic vacuolation of principally zone 3 hepatocytes. Immunohistochemical stains revealed Mcyst predominantly within pericanalicular regions of zone 3 hepatocytes. It was concluded that prolonged exposure to sublethal concentrations of Mcyst results in multiple dose-dependent hepatotoxic effects that correspond to decreased hepatic serine/threonine protein phosphatase activity and increasing cytosolic Mcyst concentrations. The disproportional increase of hepatic Mcyst concentrations observed may suggest the bioaccumulation of toxin and an increasing relative risk of hepatotOXicity With increasing dose. © 1998 Society of Toxicology.
Key Words: apoptosis; histopathology; immunohistochemistry; 1 To whom correspondence should be addressed.
liver; microcystin-LR; protein phosphatase; rats; serum biochemistry; toxin.
Microcystin-LR (Mcyst) is a naturally occurring cyclic heptapeptide hepatotoxin produced by the blue-green alga Microcystis aeruginosa. It is a potent inhibitor of serine/threonine protein phosphatase types 1 and 2A (ser/thr PP1 and PP2A). Acute illnesses and deaths in both humans and nonhuman animals following exposure to Mcyst-contaminated water sources have been reported worldwide (Barreto et ai, 1996; Beasley et ai, 1989; DeVries et ai, 1993; Falconer, 1991; Falconer et ai, 1983; Galey et ai, 1987; Gorham and Carmichael, 1988) . In instances of acute toxicity, liver damage and death result from hyperphosphorylation of cytoskeletal proteins secondary to protein phosphatase inhibition (Eriksson et ai, 1990; Falconer and Yeung, 1992; Ohta et ai, 1992; Runnegar et ai, 1993) . This in turn results in hepatic necrosis, loss of hepatocyte cell-to-cell adhesion, and fatal intrahepatic hemorrhage (Falconer et ai, 1981; Hooser et ai, 1989; Theiss et ai, 1988) . Liver mass invariably increases (Beasley etai, 1989; Dahleme/a/., 1989; Falconer et ai, 1981; Hooser et ai, 1989) . Tumor necrosis factor has also been proposed to contribute to acute hepatic damage (Nakano et ai, 1991) .
Compared with acute toxicity studies, the hepatotoxic effects of prolonged, sublethal exposure to Mcyst have been investigated to only a limited extent (Carbiss et ai, 1994; Elleman et ai, 1978; Falconer et ai, 1988 Falconer et ai, , 1994 . Chronic toxicity could become an important form of exposure as sewer and fertilizer runoff increases the frequency of algal blooms and increasing population pressures force the consumption of marginal water supplies. In the limited number of studies done, evidence of hepatic damage has included hepatocellular degeneration, single-cell necrosis, fibrosis, neutrophil infiltrates, and tumor promotion (Elleman et ai, 1978; Falconer et ai, 1988 Falconer et ai, , 1994 Nishiwaki-Matsushima et ai, 1992) . At least some of these changes appear to be dose dependent; however, the mechanism of toxicity is still poorly understood. Although it has not been documented, it seems likely that damage from prolonged exposure to sublethal concentrations of Mcyst results from decreased hepatic ser/thr PP1 and PP2A activity. If so, the severity of protein phosphatase inhibition would be expected to correlate to both increasing hepatic Mcyst concentrations and evidence of hepatic disease.
The purpose of this study was to establish the relationship of sublethal dosages of Mcyst over prolonged periods to observable hepatotoxic effects, hepatic Mcyst concentrations, and protein phosphatase inhibition. As our goal was to test the effects of Mcyst on the liver, mini-osmotic pumps were used to deliver to rats a continuous intraperitoneal (ip) infusion of purified Mcyst for 28 days. This mechanism of toxin delivery was selected over oral methods to eliminate any variability to hepatic Mcyst concentrations that may occur from variations in intestinal absorption. Continuous ip infusion was selected over ip boluses to eliminate the effect of time of sampling after dose as a potential factor affecting the measured test parameters.
METHODS
Placement of osmotic minipumps. Purified Mcyst (greater than 98% purity by HPLC, obtained from Dr. Wayne Carmichael, Wright State University, Dayton, OH) was dissolved in sterile saline and diluted to produce solutions that would deliver 3, 6, or 9 p.g Mcyst per day (16, 32, and 48 /xg/kg/day, respectively). Five Alzet osmotic pumps (Model 2004, Alza Scientific Products, Palo Alto, CA) were filled with each concentration of toxin. Five additional pumps, filled with sterile saline, served as controls. Prior to use, the pumps were primed by storage in individual sealed test tubes of sterile saline at 37°C for 2 days. The pumps were then placed into the peritoneal cavity of 20 male Harlan Sprague-Dawley rats (5 rats per treatment group, Harlan Sprague-Dawley, Inc., Indianapolis, IN) weighing on average 185 g each. Implantation of the pumps was performed aseptically while the rats were under general anesthesia. All 20 surgeries were completed within 3 h on the same day. Following recovery from anesthesia, all rats were housed for 28 days in the same room in individual cages under standard lighting conditions and temperatures and allowed free access to a standard lab chow. At the end of 28 days, each rat was anesthetized with ketamine and xylazine administered intraperitoneally. Each rat was then weighed, and blood taken for serum by cardiac stick. This was followed immediately by euthanasia using intracardiac pentobarbital. Each liver was immediately removed, patted dry with paper towels, and weighed. A small piece of liver from the left lateral lobe was fixed in 10% buffered formalin. The rest of the liver was immediately frozen on dry ice, then transferred to a -80°C freezer.
Histology and immunohistochemistry.
Formalin-fixed tissues were processed in a standard fashion using an automated processor and embedded in paraffin, and 3-fun sections cut and stained with H&E. Histology sections were reviewed in a blinded fashion. Ten high-power fields were examined on each section and the average number of mitotic figures and apoptotic cells and bodies per high-power field were determined. Other histological abnormalities, such as hepatocellular vacuolation, were subjectively assessed and noted for each slide.
Immunohistochemistry was done on the formalin-fixed tissues to determine whether the distribution of Mcyst in the liver coincided with regions of hepatocellular damage. Three-micrometer sections were placed on charged slides and deparaffinized in three changes of xylene followed by rehydration in a graded alcohol series. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide. Slides were then rinsed in water and two changes of pH 7.6 hypertonic wash buffer consisting of 0.1 M TRTZMA hydrochloride, 0.03 M TRIZMA base, and 0.35 M NaCl and blocked with normal goat serum.
Sections were then incubated in anti-Mcyst monoclonal antibody (Huang and Chu, 1996) . Biotinylated goat anti-mouse IgG labeled with streptavidinhorseradish peroxidase (HRP) and DAB reagent (Kirkegard & Perry Laboratories, Inc., Gaithersburg, MD) was used as the secondary antibody system. Negative controls included liver sections from saline-treated rats and liver sections from Mcyst-treated rats incubated in nonreactive monoclonal antibody (anti-canine alkaline phosphatase) rather than anti-Mcyst antibody.
In situ end-labeling (ISEL) of paraffin-embedded liver sections was used to confirm the presence of DNA fragmentation in suspected apoptotic cells. A commercially available kit (FragEL, Oncogene Research Products, Cambridge, MA) was used to perform the assays. Briefly, Klenow enzyme was used to incorporate biotin-labeled nucleotides onto the exposed 3'-OH ends of nuclear DNA fragments. The sections were then incubated with streptavidin-HRP, followed by DAB reagent, and then counterstained. Apoptosis-negative and apoptosis-positive control slides were run concurrently.
Serum chemistries. An automated analyzer (Hitachi 911, BoehringerMannheim, Indianapolis, IN) was used for all serum chemistries. Serum harvested from each rat at the time of euthanasia was used to determine serum activity of alanine aminotransferase (ALT), sorbitol dehydrogenase (SDH), aspartate aminotransferase (AST), -y-glutamyl transferase (GGT), and serum total alkaline phosphatase (ALP). Serum total bilirubin and total bile acid concentrations were also measured. The serum activity of the liver alkaline phosphatase isozyme (LALP) was determined using wheat germ lectin binding and levamisole inhibition assays as previously described (Hoffman et al., 1994) . Serum albumin concentrations and total protein were measured and the albumin/globulin (A/G) ratio was determined. Test kits from Boehringer-Mannheim were used for all assays except SDH and total bile acids, the kits for which were from Sigma Chemical Company (St. Louis, MO). Serum total bile acid concentrations were determined as previously described (Solter et al., 1992) .
Measurement of hepatic protein phosphatase activity. Hepatic PP1 and PP2A activity was measured by assessing the release of inorganic [
32 P]phosphate from [ 32 P]phosphorylase a at 30°C (Hamm-Alvarez, et al., 19%; Runnegar el al., 1993) . About 1 g of liver was accurately weighed and homogenized in 50 mM pH 7.0 Tris-HCl containing 1 mM dithiothreitol (DTT), 0.1 mM EDTA, 1% Nonidet, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 1 jig/ml pepstatin, and 0.5 jig/ml leupeptin. Prior to assay, supernatant fluids prepared from these homogenates were diluted ninefold in 50 mM Tris-HCl, pH 7.0, containing 1 mM DTT and 0.1% bovine serum albumin. Ten-microliter aliquots of the diluted samples were preincubated at 30°C in 10 jil of 50 mM Tris-HCl (pH 7.0) and 1 mM DTT, with or without 6 nM okadaic acid. Okadaic acid is an inhibitor of PP2A activity and was used to distinguish PP1 from PP2A activity. The phosphatase reaction was started by the addition of [ 32 P]phosphorylase a and was terminated after 10 min by the addition of 0.1 ml 10% trichloroacetic acid. The amount of 32 P released was measured by liquid scintillation counting of the supernatant fluid.
Measurement of liver cytosolic Mcyst concentrations.
Liver cytosolic Mcyst concentrations were determined using a direct competitive ELISA assay as previously described (Chu et al, 1989 (Chu et al, , 1990 Lin and Chu, 1994) . Briefly, approximately 1-g sections of liver tissue were accurately weighed and homogenized in 5 ml of 50 mM pH 7.4 Tris-HCl, 2 mM EDTA, 22 mM EGTA, 2 mM B-mercaptoethanol, 10% glycerol, and 0.25 M sucrose at 4°C. The liver slurries were centrifuged and the supernatant fluid containing the cytosolic fractions was saved. One-milliliter aliquots of each cytosolic fraction were then diluted with 5 ml distilled water and the pH adjusted to 3.0. Each sample was loaded onto C, 8 reversed-phase cartridges that had been pretreated with methanol and distilled water. The cartridges were washed with acidified distilled water and 20% methanol and the Mcyst was eluted with 75% methanol. The eluants were dried and reconstituted in 0.01 M phosphate-buffered saline (PBS).
Varying concentrations of Mcyst standards, PBS, and sample solution were mixed with Mcyst-HRP conjugate and added to microtiter plate wells that were precoated with anti-Mcyst polyclonal antibody. After incubation at 37°C for 60 min, the microtiter plate wells were washed with PBS/Tween followed Statistical analysis. GraphPad Prism Version 2.0 software (GraphPad Software, Inc., San Diego, CA) was used for all statistical comparisons. Differences between dose groups were evaluated by one-way analysis of variance {p £ 0.05) using Dunnett's posttest to compare mean values obtained at each dose to the control group and a posttest of trend to determine whether a significant correlation existed between toxin infusion rate and each measured parameter (Motulsky, 1997) .
RESULTS

Liver Weights and Body Weights
Weight gain over the 28-day period was significantly less in the 9 p,g per day treatment group when compared with weight gain of the controls by Dunnett's posttest (Fig. 1) . There was also a significant correlation between the dosage group and the mean weight gain of each group as determined by a posttest of trend. In contrast, there was no statistical difference in the body weight/liver weight ratios between groups.
Histology and Immunohistochemistry
H&E-stained liver sections revealed the presence of apoptotic cells in rats receiving 6 or 9 /ig of Mcyst per day (Fig. 2) . Apoptotic cells, apoptotic bodies, and clear cystoplasmic vacuolation were most common in the pericentral (zone 3) regions of the hepatic lobules of the rats receiving 6 or 9 jig of Mcyst per day. The ISEL staining procedure confirmed the presence of apoptotic cells in the sections from Mcyst-treated rats (Fig. 3) .
The results of quantification of the number of apoptotic cells and bodies, mitotic figures, and cytoplasmic vacuolation in each treatment group are summarized in Table 1 . Apoptotic changes and hepatocellular vacuolation were most common in the rats receiving 6 and 9 pig of Mcyst per day. The quantification of the number of apoptotic cells and bodies was skewed in the group of rats receiving 6 ^g of Mcyst per day due to a large number of such changes in one rat of the group. The median values are therefore more representative of the typical alterations observed in each group. The number of mitotic figures did not vary between groups.
Immunohistochemistry revealed Mcyst staining that was most intense within hepatocytes in zone 3 regions (Fig. 4) . Mild staining of zone 1, in addition to zone 3, was noted in some fields of the 9 ^.g/day treatment group. The pattern of staining within individual hepatocytes was cytoplasmic with occasionally increased intensity in perinuclear zones. More commonly, immunodetection of Mcyst was most intense in apical regions, suggesting subcellular concentrations of the toxin near bile canaliculi. Staining in these regions was frequently granular in nature. There was also pronounced cytoplasmic Mcyst staining of many of the apoptotic cells.
Serum Chemistries
Serum AST and SDH activities were significantly increased over those of saline-treated control rats in the highest dosage groups (Fig. 5) . There was also a significant correlation between the dose of toxin infused and the magnitude of the increase in these two parameters. In addition, with increasing Mcyst dosage, there was a progressive decrease in serum albumin concentrations while serum total protein concentrations did not change (Fig. 5) . This resulted in a progressive decrease in the A/G ratio. Alkaline phosphatase isozyme analysis revealed a dose-dependent increase in LALP isozyme activity (Fig. 6) . GGT activity and serum total bile acid concentrations also increased in a dose-dependent manner (Fig. 6) . A significant difference was not detected in mean serum total bilirubin concentration or mean ALT activity between any treatment group and the saline-treated controls.
Hepatic Protein Phosphatase Activity and Mcyst Concentration
Hepatic activity of both PP1 and PP2A were significantly decreased in the Mcyst-treated rats relative to the saline-treated controls. For both enzymes, phosphatase activity progressively decreased as the dosage of Mcyst given increased (Fig. 7) . Hepatic PP2A activity was relatively more severely affected than PP1 activity, falling to near-undetectable levels in the 6 and 9 /xg/day treatment groups, while PP1 activity in the 6 and 9 /xg/day treatment groups was still 42 and 31 % of the control value, respectively.
Hepatic cytosolic Mcyst concentrations progressively increased with increasing dosage of Mcyst given (Fig. 7) . However, this increase occurred at a greater rate than would be predicted based on the incremental increase in dose given. For example, when the dose of Mcyst given was doubled from 3 to 6 /ig/day, the mean liver cytosol Mcyst concentration increased 4.3-fold (from 147 ± 50.7 to 633 ± 145ng/g). When the Mcyst dosage was increased 3-fold, from 3 to 9 /xg/day, the mean hepatic Mcyst concentration increased 13.6-fold (1996 ± 142 ng/g). Of the total amount of Mcyst given to each rat, the average percentage of total FIG. 3 . In situ end labeling (ISEL) of liver sections from the same rat as shown in Fig. 2 . Both panels show the intense staining of the chromatin in apoptotic cells (arrows) consistent with DNA fragmentation. 1000X. Note. There were five rats per treatment group. " High-power field.
dose present in the liver cytosol at the time of euthanasia increased from 2.4% at the 3 /xg/day dose to 4.6% at the 6 fig/day dose and 9.1% at the 9 jig/day dose. The rat that had the disproportional increase in the number of apoptotic cells for its treatment group also had a substantially higher liver cytosol Mcyst concentration (1159 ng/g tissue) than the other four rats in the 6 /ig/day dosage group, the (± SD) mean Mcyst concentration of which was 502 (±) 159 ng/g.
DISCUSSION
This study confirmed an inverse, dose-dependent relationship between liver cytosol Mcyst concentrations and hepatic protein phosphatase type 1 and 2A activity, consistent with the anticipated toxic effect of Mcyst. The dose-related nature of both protein phosphatase inhibition and evidence of hepatotoxicity is consistent with the observed hepatotoxic effects stemming from prolonged ser/thr protein phosphatase inhibition. In vitro, Mcyst is an equipotent inhibitor of PPl and PP2A (MacKintosh et al, 1990; Takai et al, 1995; Toivola et al., 1994) . In contrast, this study showed a greater effect of Mcyst on PP2A activity than on PPl activity. For example, at a Mcyst dosage of 6 jig/day, PP2A activity approached undetectable levels while PPl activity was still 42% of control. Hence, in vivo, PP2A may be more sensitive to Mcyst inhibition than PPl. This difference may reflect the fact that, in vivo, the catalytic subunits of PPl and PP2A are associated with several different regulatory subunits that could influence the specificity, intracellular localization, and sensitivity to activators and inhibitors (Shenolikar, 1994) .
There was also observed a dose-dependent increase in cytosolic Mcyst concentrations as measured by ELISA. It is well known that most of the Mcyst in liver tissue is recovered from the cytosolic fraction (Hooser et al, 1991b; Lin and Chu, 1994; Robinson et al, 1991) . However, some portion of Mcyst may bind covalently to protein phosphatases and therefore may not be immunoreactive to the a-Mcyst antibodies (Craig et al., 1996; Mackintosh et al, 1995; Robinson et al, 1991; Runnegar et al, 1995b; Williams et al, 1997) . If so, the Mcyst concentrations observed in this study underestimate the total Mcyst present in the liver at the time of sampling. The amount of Mcyst metabolized or excreted by hepatocytes could therefore be lower than that suggested by this study. Robinson etal. (1991) found that, in mice, little radiolabeled [ 3 H]Mcyst was lost from liver cytosol up to 6 days following a single intravenous injection of 35 /Ag/kg, a dose that resulted in only transient serum biochemical evidence of hepatic damage and no apparent histological effects. The results of other experiments suggest that retention of Mcyst by the liver is dependent on whether the liver had suffered damage (Runnegar et al, 1986) . In the latter experiments, badly damaged livers retained toxin, while undamaged or only mildly affected livers as assessed histologically retained little reactivity. In the current study, as the degree of hepatotoxicity increased, the relative amount of Mcyst retained by the liver increased. We believe that the combined results of these studies suggest that the metabolism and/or excretion of Mcyst from the liver is dose dependent, which would explain the observed progressive increase in the percentage of toxin retained by the liver. Hence, either the liver has a limited ability to excrete Mcyst or the toxin itself inhibits its own hepatic clearance, resulting in a dose-dependent buildup that is disproportional to the increase of dose given. The clinical relevance of this is that relatively minor increases in the level of exposure to Mcyst will result in disproportionately greater risks of hepatotoxicity.
There are many means by which Mcyst could potentially inhibit its own metabolism and/or excretion from the liver. For example, detoxification of Mcyst likely involves glutathione and cysteine conjugation (Kondo et al, 1996) . Interference by Mcyst with either the synthesis of glutathione or the metabolism of glutathione conjugates could therefore affect its metabolism. Decreased biliary excretion of toxin could be caused by inhibition of microtubule function, which has been shown to play a role in bile formation and excretion of organic anions (Crawford et al., 1988) . Decreased hepatic excretory function could also be due to inhibition of other cytoskeletal proteins by Mcyst. For example, actin filaments are particularly abundant around bile canaliculi and may be involved in canalicular contractions, which are considered important to bile flow (Ishii et al, 1991; Watanabe et al, 1988) . Mcyst disrupts actin microfilaments (Hooser et al, 1991a) . Hepatocytes in all regions of the liver lobule have the ability to clear bile acids from the blood, although periportal (zone 1) hepatocytes are principally responsible for bile acid clearance (Groothius et al, 1997; Gumucio et al., 1978; Jones et al, 1980) . It has recently been shown that hepatic clearance of Mcyst does not involve any of the well-char- (Runnegar et al., 1995a) . The distribution of the transporter mechanism responsible for Mcyst clearance has not been determined, nor is the distribution of protein phosphatases in the liver known, although all cells have protein phosphatase, so there should not be a significant gradient of intracellular targets along the hepatic plate. Additional studies are needed to better define the mechanism of Mcyst clearance from the blood.
Coinciding with the zone 3 location of Mcyst was the presence of increased hepatocellular apoptosis and vacuolization in the same regions. In addition, apoptotic cells stained positively for the presence of Mcyst, suggesting a cause-effect relationship between Mcyst uptake and apoptosis. Induction of apoptosis by ser/thr protein phosphatase inhibitors is well known (Boe et al., 1991) . In addition, hepatocellular apoptosis secondary to acute Mcyst toxicity in mice has also been described recently (Yoshida et al., 1997) . In contrast to the current findings, the results of many acute toxicity studies describe hepatocellular necrosis and intrahepatic hemorrhage secondary to Mcyst intoxication Miura et al., 1989; Yoshida et al, 1997) . It is likely that the slow induction of hepatotoxicity by prolonged protein phosphatase inhibition is responsible for the differing signs of toxicity.
An additional histological effect on hepatocyte morphology was the development of cytoplasmic vacuoles in several hepatocytes. While at this point, we have been unable to fully investigate the cause of this vacuolation, we suspect that these are likely lipid vacuoles. Further investigation of the nature of these vacuoles seems warranted because if they truly represent lipid, an additional hepatotoxic effect of prolonged Mcyst exposure may be deranged lipid metabolism or fatty change.
In addition to evidence of hepatocellular disease, decreased weight gain in our highest treatment group, was also seen. A similar phenomenon has been observed following oral treatment of swine with Microcystis over a period of 9 weeks (Falconer et al., 1994) . The cause of this decrease is not readily evident, although food consumption was not monitored, and decreased caloric intake could not be ruled out.
This study also showed multiple dose-related serum biochemical effects of microcystin-LR following prolonged sublethal exposure. Increased serum activity of enzymes considered indicative of hepatocellular damage has been previously observed in both acute and chronic toxicity studies (Falconer, 1991; Falconer et al., 1988 Falconer et al., , 1994 Hermansky et al, 1991; Hooser etal, 1989; Miura etal, 1989; Runnegar and Falconer, 1982) . Our results confirm that serum biochemical evidence indicative of hepatocellular damage and dysfunction is induced by prolonged exposure to sublethal dosages of Mcyst in a largely dose-dependent manner. Evidence in serum of hepatotoxiciry included biochemical abnormalities usually associated with hepatocellular damage or necrosis (AST and SDH), cholestasis (LALP, GGT and bile acids), and hepatic protein synthesis (albumin).
CONCLUSION
This study documents a dose-dependent relationship between liver cytosol Mcyst concentrations, the severity of hepatic ser/thr protein phosphatase inhibition, and worsening evidence of hepatotoxicity. Numerous hepatotoxic effects resulted from prolonged exposure to sublethal dosages of microcystin-LR. This is likely due to the multiple contributions of ser/thr protein phosphatases to hepatocellular function. The disproportional increase in liver cytosol Mcyst concentrations relative to the incremental increase of dose given suggests that Mcyst may be inhibiting its own metabolism and/or excretion and that the risk of hepatotoxicity may also increase in a disproportionate way.
